|By Business Wire||
|June 26, 2014 01:10 PM EDT||
The 2014 BIO International Convention, the world’s largest biotechnology event, enters its fourth and final day today at the San Diego Convention Center. Hosted by the Biotechnology Industry Organization, this year’s event is expected to attract more than 3,000 biotechnology companies and more than 15,000 attendees from 48 states and 65 countries.
Upcoming Convention Highlights Include:
Super Session: Scientific
American WorldView Super Session - Biotech: We are the World,
Thursday, June 26
What is happening in biotechnology and life science development on the global stage? What are the most pressing issues of our time that have every nation looking to science as a solution? As the world continues to flatten, individual countries are finding new ways to grow their innovation engines, and in some cases, are hoping to outshine the US. Come to the annual Scientific American WorldView super session to hear a dynamic panel of international industry luminaries examine the future of global innovation in a lively candid conversation. Moderated by television and radio journalist, David Brancaccio, host of Marketplace Morning Report, this session will explore key themes from Scientific American’s annual biotechnology edition, featuring the WorldView Scorecard and fresh perspectives on international life science development.
Super Session: The
Next Big Deal: The Global Dealmaker Perspective, Thursday,
2013 delivered in a big way for each of the major deal-making outlets with nearly three times the number of IPOs as in 2012. The M&A market opened up with the total dollars spent on acquisitions reaching the highest in five years. Strong deal terms with large upfront payments for early stage assets were also seen in 2013 as exemplified with Moderna’s $240M upfront from Astrazeneca and Oncomed’s $177M upfront from Celgene. Will these upward trends continue? How will these changing dynamics impact dealmaking in the coming year? What do dealmakers expect will be the result in 2014? Campbell Alliance and BIO are pleased to present updated findings from two unique forward-looking measures of dealmaking in the industry – the Campbell Alliance Dealmakers’ Intentions Study and the BIO One-on-One Partnering Forecast. Based on a survey of more than 150 industry executives, business development professionals, and financial institutions, Dealmakers’ Intentions provides insight into what will likely drive the industry’s partnering and M&A efforts moving forward, and the implications for deal-making over the next year or more. Now in its sixth year, new analysis in 2014 will include year-over-year trends, additional deal metrics, and broader M&A data. Incorporating a global perspective, a highly distinguished panel of dealmakers will then explore the impact these market forces will have on pharmaceutical and biotech companies as they position themselves to make that next big deal.
Idea Hack hosted by MIT H@cking Medicine, Thursday, June 26
With advances in technology, transformative government incentives, and increasing partnerships, now is the best time in history to be a healthcare entrepreneur. Those with a fresh take on healthcare's pain points, including industry professionals along with patients, engineers, designers and entrepreneurs, have the ability to make a sizable and rapid impact. This gathering of diverse perspectives will bring industry stakeholders, clinicians, entrepreneurs, and engineers together to tackle complex health challenges with the aim to innovate testable, fundable solutions.
Technologies to Save Us In a Disaster: Opportunities in the
Public-Private Partnership to Develop Medical Countermeasures,
Thursday, June 26
In the decade since the US Congress adopted Project Bioshield, more than $5 billion has been invested in the biodefense sector. This session will explore recent trends and new developments in the advanced development of medical countermeasures (MCMs). The session will provide an update on the status of the Centers of Innovation for Advanced Development and Manufacture and opportunities for drug developers. It will also provide perspectives on the need for novel technologies and key considerations for companies entering the biodefense sector as it matures.
Salford Lung Study: An Innovative 'Real World' Study Design for
Chronic Conditions, Thursday, June 26
The 12-month Salford (UK) Lung Study uses an integrated electronic patient record to assess the safety and effectiveness of Relovair, GlaxoSmithKline's late-phase follow-up to Advair, in chronic obstructive pulmonary disease and asthma. Results are intended to help healthcare decision- makers better assess the drug's potential at an earlier stage. The panel will address the complexities of “real-world” studies and how healthcare providers and regulators can use the data generated to understand the benefits of such studies, particularly for chronic conditions managed in community settings.
Critical Path Initiative: Progress in the First Decade and Promise for
the Next, Thursday, June 26
In 2004, the FDA launched the Critical Path Initiative (CPI), which was a response to the needs and challenges faced by medical product developers. Recognizing that no one organization possesses the resources and expertise to solve medical product development problems, the CPI called for a consortium or public-private-partnership approach to modernize the process whereby FDA-regulated products are developed and evaluated. A brief videotaped overview of the CPI will be provided by its chief architect, Dr. Janet Woodcock (CDER/FDA). Then speakers from the FDA, and industry and non-profit organizations will reflect on certain aspects of CPI that have been accomplished through consortia, present the challenges faced by organizations working in the "pre-competitive" space, and explore options for optimizing future collaborations.
Battle of the Wits 2014, Thursday, June 26
Back for its third year, well-known biotech journalist Chris Morrison will emcee this rapid-fire, interactive debate on the industry’s hot-button issues featuring three biotech trendsetters. Listen as panelists provide their off-the-cuff opinions on the industry’s most controversial and topical issues. What is the strangest biotech idea you’ve come across? How can a company bounce back from a Phase III failure? To drive the debate, audience members can ask questions live or via Twitter (@BioBanter) and vote for presenters online via Twitter or text. The winner of this session will receive 120 uninterrupted seconds to sound off on the topic of their choice.
Career Fair, Thursday, June 26
The 2014 BIO Career Fair is free to all job seekers. Co-located with the 2014 BIO International Convention, the BIO Career Fair will give attendees access to many of the world’s leading life science companies.
Day Three Session Highlights Included:
Keynote Luncheon: Hillary
Rodham Clinton, Former Secretary of State
Former Secretary of State Hillary Rodham Clinton sat down with BIO President & CEO Jim Greenwood for a special Keynote Luncheon.
Super Session: AMP-lifying
Innovation: NIH, Patient Organizations & Leading Biopharma Firms
Mobilize to Tackle Tough Diseases
The Accelerating Medicines Partnerships (AMP) is a new venture among the NIH, several non-profit organizations and 10 biopharmaceutical companies focused on transforming the current model for developing new treatments. The Session highlighted the goals and implementation plans for the new AMP program and explored the evolution of large-scale public private partnerships in an evolving innovation ecosystem.
Super Session – Beyond Borders 2014 – Unlocking Value
More than 500 attended the super session to review key findings in the 28th annual EY Global Life Sciences Report: Beyond Borders, Unlocking Value.
The Convention program features more than 160 sessions in 8 breakout sessions and 9 specialty forums. The majority of attendees, 70 percent, are c-level executives. They split evenly from large companies of 500 or more employees and small companies of 50 employees or less.
The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on major trends affecting the industry. The Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. Visit http://convention.bio.org/program/ for the most up-to-date program and speaker information.
The Convention also features the BIO Business Forum, which has grown over the past thirteen years to become the industry's largest partnering event. This year’s Convention is set to break all previous partnering records, with over 28,000 meetings expected to take place. Powered by BIO's One-on-One Partnering™ System, the BIO Business Forum™ fosters the opportunity for companies to initiate business contacts in a friendly environment and schedule private meetings prior to the Convention.
Upcoming BIO Events
Latin America Conference
September 9-11, 2014
Rio de Janeiro, Brazil
September 16-18, 2014
Sioux Falls, SD
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.